TWST:NSD-Twist Bioscience Corp (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 52.3

Change

0.00 (0.00)%

Market Cap

USD 3.12B

Volume

0.88M

Analyst Target

USD 75.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-09 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+5.13 (+1.12%)

USD 34.56B
NTRA Natera Inc

-0.63 (-0.36%)

USD 23.36B
ILMN Illumina Inc

-6.07 (-5.47%)

USD 21.05B
ICLR ICON PLC

-2.61 (-1.35%)

USD 16.55B
MEDP Medpace Holdings Inc

+0.41 (+0.12%)

USD 10.85B
EXAS EXACT Sciences Corporation

-1.15 (-2.15%)

USD 9.58B
GH Guardant Health Inc

-0.07 (-0.16%)

USD 5.49B
RDNT RadNet Inc

-0.42 (-0.67%)

USD 4.43B
SHC Sotera Health Co

+0.23 (+1.69%)

USD 3.91B
VCYT Veracyte Inc

+0.37 (+0.89%)

USD 3.40B

ETFs Containing TWST

ARCG:LSE ARK Genomic Revolution UC.. 8.77 % 0.00 %

-6.33 (-1.28%)

USD 5.84M
ARKG:LSE ARK Genomic Revolution UC.. 8.77 % 0.00 %

-0.06 (-1.28%)

USD 5.84M
IDNA iShares Genomics Immunolo.. 4.37 % 0.00 %

-0.03 (-1.28%)

USD 0.12B
EDOC:SW Global X Telemedicine & D.. 4.25 % 0.00 %

+0.06 (+-1.28%)

N/A
WDNA:LSE WisdomTree BioRevolution .. 4.11 % 0.00 %

-0.25 (-1.28%)

N/A
WDNA WisdomTree BioRevolution .. 4.03 % 0.00 %

-0.21 (-1.28%)

USD 2.27M
WBIO:LSE WisdomTree BioRevolution .. 4.02 % 0.00 %

-17.50 (-1.28%)

USD 3.82M
WRNA:XETRA WisdomTree BioRevolution .. 3.71 % 0.00 %

-0.10 (-1.28%)

USD 2.77M
CDNA:CA CI Bio-Revolution Index E.. 2.77 % 0.00 %

-0.19 (-1.28%)

CAD 6.78M
ARKG ARK Genomic Revolution ET.. 0.00 % 0.75 %

-0.51 (-1.28%)

USD 1.10B
FYX:LSE 0.00 % 0.00 %

N/A

N/A
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.55% 82% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.55% 82% B 83% B
Trailing 12 Months  
Capital Gain 36.95% 76% C+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.95% 76% C+ 80% B-
Trailing 5 Years  
Capital Gain 71.48% 86% B+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.48% 86% B+ 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 35.30% 72% C 83% B
Dividend Return 35.30% 72% C 82% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 119.49% 30% F 18% F
Risk Adjusted Return 29.54% 84% B 61% D-
Market Capitalization 3.12B 76% C+ 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.